Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.21037/atm.2017.04.04 http://scihub22266oqcxt.onion/10.21037/atm.2017.04.04 C5451622!5451622!28603723     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Transl+Med 2017 ; 5 (10): ä Nephropedia Template TP {{tp|p=28603723|t=2017. Biomarker-guided antibiotic therapy?strengths and limitations |pdf=|usr=}}{{28603723}} gab.com Text Biomarker-guided antibiotic therapy strengths and limitations JO: Ann Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=28603723 #FOAvip Biomarkers as C-reactive protein (CRP) and procalcitonin (PCT) emerged as tools to help clinicians to diagnose infection and to properly initiate and define the duration of antibiotic therapy. Several randomized controlled trials, including adult critically ill patients, showed that PCT-guided antibiotic stewardship was repeatedly associated with a decrease in the duration of antibiotic therapy with no apparent harm. There are however some relevant limitations in these trials namely the low rate of compliance of PCT-guided algorithms, the high rate of exclusion (without including common clinical situations and pathogens) and the long duration of antibiotic therapy in control groups. Such limitations weakened the real impact of such algorithms in the clinical decision-making process and strengthened the concept that the initiation and the duration of antibiotic therapy cannot depend solely on a biomarker. Future efforts should address these limitations in order to better clarify the role of biomarkers on the complex and multifactorial issue of antibiotic management and to deeply understand its potential effect on mortality. Twit Text FOAVip Biomarker-guided antibiotic therapy strengths and limitations ????Ann Transl Med http://www.kidney.de/pget.php?&tw=1&pmid=28603723 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28603723 #FOAvip English Wikipedia <ref>{{Cite pmid|28603723}}</ref> Biomarker-guided antibiotic therapy?strengths and limitations #MMPMID28603723 Nora D; Salluh J; Martin-Loeches I; Póvoa P Ann Transl Med 2017[May]; 5 (10): ä PMID28603723show ga Biomarkers as C-reactive protein (CRP) and procalcitonin (PCT) emerged as tools to help clinicians to diagnose infection and to properly initiate and define the duration of antibiotic therapy. Several randomized controlled trials, including adult critically ill patients, showed that PCT-guided antibiotic stewardship was repeatedly associated with a decrease in the duration of antibiotic therapy with no apparent harm. There are however some relevant limitations in these trials namely the low rate of compliance of PCT-guided algorithms, the high rate of exclusion (without including common clinical situations and pathogens) and the long duration of antibiotic therapy in control groups. Such limitations weakened the real impact of such algorithms in the clinical decision-making process and strengthened the concept that the initiation and the duration of antibiotic therapy cannot depend solely on a biomarker. Future efforts should address these limitations in order to better clarify the role of biomarkers on the complex and multifactorial issue of antibiotic management and to deeply understand its potential effect on mortality. äBiomarker-guided antibiotic therapy?strengths and limitations (epmc).pdf DeepDyve Pubget Overpricing